Trial Profile
A real-world study to evaluate the virological effectiveness of a Switch to Dolutegravir-containing regimens from Raltegravir-containing regimens in patients with HIV
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Aug 2018
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 29 Aug 2018 New trial record
- 27 Jul 2018 Results presented at the 22nd International AIDS Conference